The PRIMAVERA study protocol design: Evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease

Contemporary Clinical Trials

Volumn 32, Issue 6, 2011, Pages 786-792

  Fliser, D ^a   Dellanna, F ^b   Koch, M ^c   Seufert, J ^d   Witzke, O ^e   Hauser, I A ^f  

^a SAARLAND UNIVERSITY   (Germany)

^b Dialysis Centre   (Germany)

^c Centre of Nephrology   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

C.E.R.A.; CKD; ESA; Mircera; Nephrotoxicity; Progression; Renoprotection

Indexed keywords

ALBUMIN; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CREATININE; CYSTATIN C; PLACEBO;

ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANEMIA; ERYTHROPOIESIS; ERYTHROPOIETIN; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80053383294     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2011.06.008     Document Type: Article

References (58)

1. Fishbane S. Anemia and cardiovascular risk in the patient with kidney disease. Heart Fail Clin 2008, 4:401-410.
2. Kovesdy C.P., Trivedi B.K., Kalantar-Zadeh K., Anderson J.E. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006, 69:560-564.
3. Finkelstein F.O., Story K., Firanek C., Mendelssohn D., Barre P., Takano T., et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009, 4:33-38.
4. KDOQI KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007, 50:471-530.
5. Drueke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 335:2071-2084.
6. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
7. Ritz E., Laville M., Bilous R.W., O'Donoghue D., Scherhag A., Burger U., et al. Anemia Correction in Diabetes Study Investigators. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007, 49:194-207.
8. Pfeffer M.A., Burdmann E.A., Chen C.-Y., Cooper M.E., de Zeeuw D., Eckardt K.U., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New Engl J Med 2009, 361:2019-2032.
9. Solomon S.E., Uno H., Lewis E.F., Eckardt K.U., Lin J., Burdmann E.A., et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010, 363:1146-1155.
10. Rossert J., Levin A., Roger S.D., Hörl W.H., Fouqueray B., Gassmann-Mayer C., et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006, 47:738-750.
11. Gouva C., Nikolopoulos P., Ioannidis J.P., Siamopoulos K.C. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004, 66:753-760.
12. Tapolyai M., Kadomatsu S., Perera-Chong M. r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline. BMC Nephrol 2003, 4:3.
13. Jungers P., Choukroun G., Oualim Z., Robino C., Nguyen A.T., Man N.K. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001, 16:307-312.
14. Hebert L.A., Wilmer W.A., Falkenhain M.E., Ladson-Wofford S.E., Nahman N.S., Rovin B.H. Renoprotection: one or many therapies?. Kidney Int 2001, 59:1211-1226.
15. Kuriyama A., Tomonari H., Yoshida H., Hashimoto T., Kawaguchi Y., Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997, 77:176-185.
16. Fliser D., Bahlmann F.H., Haller H. EPO: renoprotection beyond anemia correction. Pediatr Nephrol 2006, 21:1785-1789.
17. Rossert J., Fouqueray B., Boffa J.J. Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 2003, 14(7 Suppl 2):S173-S177.
18. Bogoyevitch M.A. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 2004, 63:208-216.
19. Sinclair A.M., Coxon A., McCaffery I., Kaufman S., Paweletz K., Liu L., et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010, 115:4264-4272.
20. LV d'Uscio, Smith L.A., Santhanam A.V., Richardson D., Nath K.A., Katrusic Z.S. Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension 2007, 49:1142-1148.
21. Bahlmann F.H., Song R., Boehm S.M., Mengel M., von Wasielewski R., Lindschau C., et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004, 110:1006-1012.
22. Menne J., Park J.-K., Shushakova N., Mengel M., Meier M., Fliser D. The Continuous Erythropoietin Receptor Activator affects different pathways of diabetic renal injury. J Am Soc Nephrol 2007, 18:2046-2053.
23. Bergmann M., Haufe S., von Knobelsdorff-Brenckhahn F., Mehling H., Wassmuth R., Muench I., et al. A pilot study on chronic low-dose epoetin-β following PCI suggests safety, feasibility and efficacy in patients with symptomatic ischemic heart failure. Eur J Heart Failure 2011, 13(5):560-568.
24. Macdougall I.C., Robson R., Opatrna S., Liogier X., Pannier A., Jordan P., et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006, 1:1211-1215.
25. Jarsch M., Brandt M., Lanzendörfer M., Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008, 81:63-69.
26. Rossert J., Froissart M., Jacquot C. Anemia management and chronic renal failure progression. Kidney Int 2005, 99(Suppl 99):S76-S81.
27. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
28. Levey A.S., Atkins R., Coresh J., Cohen E.P., Collins A.J., Eckardt K.U., et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007, 72:247-259.
29. Matsushita K., van der Velde M., Astor B.C., Woodward M., Levey A.S., de Jong P.E., et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073-2081.
30. Lambers Heerspink H.J., Gansevoort R.T., Brenner B.M., Cooper M.E., Parving H.H., Shahinfar S., et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol 2010, 21:1355-1360.
31. Ninomiya T., Perkovic V., de Galan B.E., Zoungas S., Pillai A., Jardine M., et al. ADVANCE Collaborative Group.Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009, 20:1813-1821.
32. Keane W.F., Brenner B.M., de Zeeuw D., Grunfeld J.P., McGill J., Mitch W.E., et al. RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003, 63:1499-1507.
33. Gansevoort R.T., de Jong P.E. The case for using albuminuria in staging chronic kidney disease. J Am Soc Nephrol 2009, 20:465-468.
34. Hemmelgarn B.R., Manns B.J., Lloyd A., James M.T., Klarenbach S., Quinn R.R., et al. Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010, 303:423-429.
35. Ruggenenti P., Perna A., Mosconi L., Pisoni R., Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 1998, 53:1209-1216.
36. Lok C.E., Oliver M.J., Rothwell D.M., Hux J.E. The growing volume of diabetes-related dialysis: a population based study. Nephrol Dial Transplant 2004, 19:3098-3103.
37. Marcén R., del Castillo D., Capdevila L., Fernandez-Fresnedo G., Rodrigo E., Cantarell C., et al. Achieving chronic kidney disease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain. Transplantation 2009, 87:1340-1346.
38. Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med 2010, 123(3 Suppl):S3-S11.
39. Nankivell B.J., Borrows R.J., Fung C.L.-S., O'Connell P.J., Chapman J.R., Allen R.D.M. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004, 78:557-565.
40. Molnar M.Z., Mucsi I., Macdougall I.C., Marsh J.E., Yaqoob M., Main J., et al. Prevalence and management of anaemia in renal transplant recipients: data from ten European centres. Nephron Clin Pract 2010, 117:c127-c134.
41. Thomas M.C., Tsalamandris C., MacIsaac R.J., Jerums G. The epidemiology of hemoglobin levels in patients with type 2 diabetes. Am J Kidney Dis 2006, 48:537-545.
42. Ansell D., Udayaraj U.P., Steenkamp R., Dudley C.R. Chronic renal failure in kidney transplant recipients. Do they receive optimum care? Data from the UK renal registry. Am J Transplant 2007, 7:1167-1176.
43. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007, 28:1462-1536.
44. Locatelli F., Covic A., Eckardt K.U., Wiecek A., Vanholder R. ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009, 24:348-354.
45. Mohanram A., Zhnag Z., Shahinfar S., Keane W.F., Brenner B.M., Toto R.D. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004, 66:1131-1138.
46. Vanrenterghem Y. Anaemia after renal transplantation. Nephrol Dial Transplant 2004, 19(Suppl 5):V54-V58.
47. MIRCERA® Fachinformation September 2010.
48. Szczech La, Barnhart H.X., Inrig J.K., Reddan D.N., Sapp S., Califf R.M., et al. Secondary analysis of the CHOIR trial epoetin-β dose and achieved hemoglobin outcomes. Kidney Int 2008, 74:791-798.
49. Unger E.G., Thompson A.M., Blank M.J., Temple R. Erythropoiesis-stimulating agents - time for a reevaluation. New Engl J Med 2010, 362:189-192.
50. Hallan S.I., Ritz E., Lydersen S., Romundstad S., Kvenild K., Orth S.R. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009, 20:1069-1077.
51. Soares A.A., Eyff T.F., Campani R.B., Ritter L., Camargo J.L., Silveiro S.P. Glomerular filtration rate measurement and prediction equations. Clin Chem Lab Med 2009, 47:1023-1032.
52. Hojs R., Bevc S., Ekart R., Gorenjak M., Puklavec L. Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease. Clin Nephrol 2008, 70:10-17.
53. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 2001, 345:861-869.
54. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
55. Lacey P., Carr S.J., O'Brien D., Fentum, Williams B., Paul S.K., et al. Reduced glomerular filtration rate in pre-dialysis non-diabetic chronic kidney disease patients is associated with impaired baroreceptor sensitivity and reduced vascular compliance. Clin Sci 2006, 110:101-108.
56. Coresh J., Astor B.C., Greene T., Eknoyan G., Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41:1-12.
57. Trivedi H.S., Pang M.M., Campbell A., Saab P. Slowing the progression of chronic renal failure: economic benefits and patients' perspectives. Am J Kidney Dis 2002, 39:721-729.
58. Klahr S., Levey A., Beck J., Caggiula A.W., Hunsicker L., Kusek J.W., et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994, 330:877-884.